Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | MicrobiomeTrials← Back to trialsNCT02298959
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2015-04-08Est. Completion: 2025-05-21
Enrollment target: 59 participants Locations- Moffitt Cancer Center-International Plaza, Tampa, Florida, United States
- Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
- University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Other microbiome trials you might be interested in
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell CarcinomaLocally Recurrent Laryngeal Squamous Cell CarcinomaLocally Recurrent Oral Cavity Squamous Cell CarcinomaLocally Recurrent Oropharyngeal Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell Carcinoma
Metastatic Melanoma
Metastatic Oral Cavity Squamous Cell Carcinoma
Metastatic Oropharyngeal Squamous Cell Carcinoma
Recurrent Melanoma
Stage III Hypopharyngeal Carcinoma AJCC v8
Stage III Laryngeal Cancer AJCC v8
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IV Hypopharyngeal Carcinoma AJCC v8
Stage IV Laryngeal Cancer AJCC v8
Stage IV Lip and Oral Cavity Cancer AJCC v8
Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Unresectable Melanoma
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in tr…
Phoenix, United StatesEst. completion Jan 1, 2027
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous MelanomaLocally Advanced Mucosal MelanomaMetastatic Acral MelanomaMetastatic Conjunctival MelanomaMetastatic Cutaneous MelanomaMetastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Mucosal MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Recurrent Cutaneous MelanomaRecurrent HER2-Negative Breast CarcinomaRecurrent Hormone Receptor-Positive Breast CarcinomaRecurrent Lung Non-Small Cell CarcinomaRecurrent Mucosal MelanomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Unresectable Acral MelanomaUnresectable Cutaneous MelanomaUnresectable Lung Non-Small Cell CarcinomaUnresectable Mucosal Melanoma
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-I…
Seattle, United StatesEst. completion Nov 1, 2027